Broad Institute

OCTOBER 17, 2023

He utilized industry-leading laboratory technology to design robust, repeatable experiments, including assay development, training, large screens, and follow-up assays. Soule holds a B.S. in mechanical engineering from Boston University. Contact Christian Soule via email at chsoule@broadinstitute.org.

Assay Development 52

Assay Development Laboratories Engineering Science 52

Drug Target Review

JUNE 15, 2023

Sam focuses on the application of innovative assay development strategies to enable to interrogation of complex targets. As a postdoc, Sam trained with Richard Youle and Jim Inglese at the National Institutes of Health where he first realised the potential of genome editing in drug discovery.

RNA 96

RNA Small Molecule Disease Assay Development 96

Alta Sciences

AUGUST 21, 2023

Our solutions include standalone services or integrated programs, providing assay development and top-quality data for toxicokinetic (TK) , pharmacokinetic (PK), and pharmacodynamic (PD) determinations to support your nonclinical and clinical studies. Why Partner With Altasciences for Your Bioanalytical Projects?

Assay Development 52

Assay Development Pharmacokinetics Drug Development Drugs 52

Sygnature Discovery

JANUARY 17, 2023

About SB Drug Discovery SB Drug Discovery is an industry leader in specialist contract research, providing critical data for novel drug development through cell line generation, assay development and compound screening services. SB is based in Glasgow and employs 55 people.

Compound Screening 52

Compound Screening Marketing Assay Development Drugs 52

PerkinElmer

NOVEMBER 12, 2020

These are just three of the steps to take toward reliable and replicable assay development. The post Replicable Assays: Not the Impossible Dream first appeared on PerkinElmer Blog. It’s also important to consider if plates will be compatible with your lab’s current screening instrumentation. You can find the entire list here.

Assay Development 52

Assay Development Drug Development Research Drugs 52

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments.

Virus 52

Virus Assay Development Disease Research 52

Drug Target Review

OCTOBER 3, 2024

This comprehensive toolbox of Type 1, Type 2, Type 3 and Type 4 anti-idiotypic antibodies provides PK and ADA assay developers with enhanced flexibility for a thorough analysis of antibody candidates. Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

Broad Institute

JUNE 30, 2023

LipocyteProfiler builds on the concept of image-based profiling that was first introduced in the context of morphology mapping by Cell Painting, a high-content imaging assay developed by Broad institute scientist and Imaging Platform senior director Anne Carpenter.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Drug Target Review

OCTOBER 10, 2024

Diseased material should be prioritised for disease-specific investigations, target validation, and preclinical testing for safety and efficacy, while leveraging healthy cells for basic research and assay development. Healthy cells may also serve as a valuable control in experiments.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The Agency recommended that product developers begin designing potency assay(s) early, and developing and evaluating multiple potency assays since not all potency assays can be validated and some potency assays may not fully reflect the biological activity.

Therapies 59

Therapies Engineering Production FDA 59

Drug Target Review

NOVEMBER 1, 2023

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. Although we are an academic centre we work very much like industry. The team that I lead within the CCDD is called the Hit Discovery and Structural Design Team.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

MARCH 20, 2021

A schematic of domain and functional organization of two of the major structural proteins of SARS-CoV-2, Nucleocapsid protein as a target viral antigen for assay development. Based on our discovery experiments, we decided upon nucleocapsid protein as our target antigen for assay development.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

JANUARY 27, 2021

These include in-vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.

FDA 52

FDA Synthetic Chemistry Assay Development Treatment 52

The Premier Consulting Blog

OCTOBER 26, 2022

Development of the manufacturing process description The development of the MPD is an iterative process. The MPD is best created and controlled by a sponsor, rather than by a contract development and manufacturing organization (CDMO) assigned to perform the process and assay development.

Production 40

Production Assay Development Clinical Supply Engineering 40

Elrig

APRIL 29, 2024

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Agency IQ

JULY 21, 2023

With this in mind, FOCR will work over the next few years to “establish evidence of baseline ctDNA levels by cancer type and stage across assays through a collaborative effort with multiple assay developers.”

FDA 40

FDA Clinical Trials Treatment Trials 40

Sygnature Discovery

SEPTEMBER 14, 2023

Programs have integrated Sygnature’s novel assay development and hit identification expertise with River BioMedics’ unique, state-of-the-art technology to advance human-predictive in vitro 3D heart models and its deep knowledge of cardiac biology. The two companies have collaborated in cardiovascular drug discovery since March 2021.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

Agency IQ

FEBRUARY 2, 2024

The protocol and statistical analysis plan should clearly specify the plans for specimen collection, sample analysis and related clinical outcomes depending on the biomarker assay development and validation strategy.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40